Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Author: sugaradmin

1312-OR: Effects of Physical Activity and Diabetes Status on Cognitive Function and Hippocampal Volume: The Bunkyo Health Study

June 9, 2026 by sugaradmin

Introduction and Objective: Diabetes mellitus (DM) is a major risk factor for cognitive decline and dementia, whereas physical activity (PA) may mitigate this risk. However, the combined effects of PA and DM on cognitive function and brain structure remain unclear. We examined whether PA modifies associations of DM with mild cognitive impairment (MCI) and hippocampal […]

Read More
DiabetesLeave a Comment on 1312-OR: Effects of Physical Activity and Diabetes Status on Cognitive Function and Hippocampal Volume: The Bunkyo Health Study

1344-OR: Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes

June 9, 2026 by sugaradmin

Introduction and Objective: There are limited data evaluating both A1C and CGM metrics on a population level. This study assessed Dexcom CGM use on these measures in adults with T2D on non-insulin (NIT), non-intensive insulin (NIIT) and intensive insulin (IIT) therapies.Methods: Truveta EHR data linked at the individual level to Dexcom CGM data were analyzed […]

Read More
DiabetesLeave a Comment on 1344-OR: Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes

1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates

June 9, 2026 by sugaradmin

Introduction and Objective: Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), conditions with substantial unmet medical need. This study aimed to characterize XWDAPC-1, a novel long-acting β-klotho antibody-GLP-1/GCG/GIP quadragonist, for its metabolic efficacy and pharmacological profile.Methods: The in vitro activity of XWDAPC-1 was evaluated using cell-based […]

Read More
DiabetesLeave a Comment on 1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates

1323-OR: Zenagamtide Targets Key Feeding-Related Brain Regions and Induces Weight Loss by Preferentially Reducing Consumption of Unhealthy Solid and Liquid Diets in Rats

June 9, 2026 by sugaradmin

Introduction and Objective: An unhealthy diet is associated with obesity, cardiovascular disease and death. Zenagamtide (previously amycretin) is a novel unimolecular GLP1-, amylin- and calcitonin receptor agonist that decreased body weight by up to 24.3% in patients with obesity. As it is unknown if zenagamtide also promotes healthier food choices, we investigated zenagamtide’s distribution to […]

Read More
DiabetesLeave a Comment on 1323-OR: Zenagamtide Targets Key Feeding-Related Brain Regions and Induces Weight Loss by Preferentially Reducing Consumption of Unhealthy Solid and Liquid Diets in Rats

1337-OR: The HOPE Study: An Immersive Telehealth Solution for Older Adults with Type 2 Diabetes

June 9, 2026 by sugaradmin

Introduction and Objective: Type 2 diabetes (T2DM) places older adults at risk of unhealthy aging and cognitive decline. Diabetes self-management education and support (DSME/S) is effective but underutilized. We conducted a two-arm randomized trial (DSME/S delivery via an immersive, 3D virtual environment (HOPE) versus a waitlist control group) to assess 6-month changes in glucose control […]

Read More
DiabetesLeave a Comment on 1337-OR: The HOPE Study: An Immersive Telehealth Solution for Older Adults with Type 2 Diabetes

1336-OR: A Lactate-PFKL Lactylation Positive Circuit Promotes the Progression of MASLD

June 9, 2026 by sugaradmin

Introduction and Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health challenge with limited effective pharmacological therapies. Although lysine lactylation has emerged as an important regulator of metabolic homeostasis, whether lactylation of the key glycolytic enzyme phosphofructokinase liver type (PFKL) drives MASLD progression and the underlying mechanisms remain obscure.Methods: Quantitative lactylome and […]

Read More
DiabetesLeave a Comment on 1336-OR: A Lactate-PFKL Lactylation Positive Circuit Promotes the Progression of MASLD

1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data

June 9, 2026 by sugaradmin

Introduction and Objective: Evidence for GLP-1RA-associated cardiovascular benefits in type 1 diabetes (T1D) remains scarce. Using a target trial emulation, we assessed the impact of GLP-1RA use on cardiovascular outcomes in a high-risk cohort of adults with T1D and overweight or obesity.Methods: We emulated a target trial using electronic health records from Epic COSMOS database. […]

Read More
DiabetesLeave a Comment on 1292-OR: Cardiovascular Outcomes Associated with GLP-1 Receptor Agonist Use among Adults with Type 1 Diabetes and Overweight or Obesity: A Target Trial Emulation Using Real-World EHR Data

1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation

June 9, 2026 by sugaradmin

Introduction and Objective: MASLD is a common polygenic condition, but current GWASs have only identified 14 loci due to a lack of scalable, clinically relevant phenotypes.Methods: Using machine learning on four UKBB data modalities (MRI, DXA, plasma metabolites, blood biomarkers; n=25,474 to 262,927), we predicted liver fat (LF) and adipose tissue volume (ATV), increasing statistical […]

Read More
DiabetesLeave a Comment on 1331-OR: Hepatic IRS1 as a Therapeutic Target in Metabolic Dysfunction–Associated Liver Disease (MASLD): AI/ML-Driven Genetic Discovery and In Vivo Therapeutic Validation

1302-OR: Diabetes Nurse Practitioner–Led Management in Transitional Care Center Reduced 90-Day Utilization and Costs in High-Risk Patients

June 9, 2026 by sugaradmin

Introduction and Objective: The organization’s transitional care center (TCC) has reduced overall rehospitalizations. Initiative evaluated whether DM nurse practitioner (NP) led post-discharge management in TCC, coupled with CHW support with SDOH barriers, reduces 90-day healthcare utilization and costs among people hospitalized with diabetes, compared to 90 days prior to index admission.Methods: In 2025, DM NP […]

Read More
DiabetesLeave a Comment on 1302-OR: Diabetes Nurse Practitioner–Led Management in Transitional Care Center Reduced 90-Day Utilization and Costs in High-Risk Patients

1325-OR: Deficient β-Cell Reserve and Exocrine Insufficiency Synergistically Drive Glycemic Variability in Chronic Pancreatitis

June 9, 2026 by sugaradmin

Introduction and Objective: Post-pancreatitis diabetes mellitus (PPDM-C) is characterized by dual exocrine and endocrine failure. However, the impact of exocrine insufficiency (PEI) on β-cell reserve and glycemic variability remains underdefined. This study aims to elucidate the characteristics of islet function in CP and the influence of exocrine status on glucose homeostasis.Methods: We analyzed 148 CP […]

Read More
DiabetesLeave a Comment on 1325-OR: Deficient β-Cell Reserve and Exocrine Insufficiency Synergistically Drive Glycemic Variability in Chronic Pancreatitis

Posts navigation

Older posts
Newer posts

Recent Posts

  • ‘Ozempic Feet:’ What Causes This Unusual GLP-1 Side Effect?
  • Depo-Provera, IUDs Tied to Higher Brain Tumor Risk
  • Trends in self-reported current diabetes care use, socioeconomic inequalities, and associated factors in Japan: evidence from the Comprehensive Survey of Living Conditions (1986-2022)
  • Bryan Johnson Diagnosed with Autoimmune Gastritis
  • Sam Neill, ‘Jurassic Park’ Star, Dies at 78

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness